Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 9/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16714648 | 1.00 | NR1H2 (0.43) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL17499855 | 1.00 | NR1H2 (0.43) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| Methane SCHEMBL28623117 | 0.98 | NR1H2 (0.42) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL28623116 | 0.84 | RORC (0.33) | NR1H2RORCPIK3CD | |
| SCHEMBL17630365 | 0.84 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2RORCPIK3CD | |
| SCHEMBL961345 | 0.84 | USP2 (0.42) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL15896820 | 0.84 | USP2 (0.42) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL17630680 | 0.84 | HPGD (0.47) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL1965038 | 0.84 | HPGD (0.47) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL28854713 | 0.84 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2RORCPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547658-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | Bristol-Myers Squibb Company (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119325469-A | WEE1 degrading compounds and uses thereof | 百时美施贵宝公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2024006881-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | WEE1, WEE2, PPME1 | NR1H2 3366/4885USP2 242/4885SMN1; SMN2 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.